The advent of FDA approved anti-AB drugs such as Aducanumab and Lecanemab is changing not only the therapeutic prospectives for patients but also the diagnostic flow-charts. However, due to differences in clinical processes and insurance systems in each country, the use of amyloid PET in the diagnostic tree currently varies from country to country. In Europe, […]